250 related articles for article (PubMed ID: 34348914)
1. Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium.
Barr CE; Ryan NAJ; Derbyshire AE; Wan YL; MacKintosh ML; McVey RJ; Bolton J; Fitzgerald C; Awad D; Slade RJ; Syed AA; Ammori BJ; Crosbie EJ
Cancer Prev Res (Phila); 2021 Nov; 14(11):1041-1050. PubMed ID: 34348914
[TBL] [Abstract][Full Text] [Related]
2. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
[TBL] [Abstract][Full Text] [Related]
3. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
4. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
[TBL] [Abstract][Full Text] [Related]
5. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
6. The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk.
MacKintosh ML; Derbyshire AE; McVey RJ; Bolton J; Nickkho-Amiry M; Higgins CL; Kamieniorz M; Pemberton PW; Kirmani BH; Ahmed B; Syed AA; Ammori BJ; Renehan AG; Kitchener HC; Crosbie EJ
Int J Cancer; 2019 Feb; 144(3):641-650. PubMed ID: 30289975
[TBL] [Abstract][Full Text] [Related]
7. Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia.
Matsuo K; Mandelbaum RS; Ciccone M; Khoshchehreh M; Pursuwani H; Morocco EB; Matsuzaki S; Dancz CE; Ozel B; Paulson RJ; Roman L
Int J Gynecol Cancer; 2020 Sep; 30(9):1331-1339. PubMed ID: 32376736
[TBL] [Abstract][Full Text] [Related]
8. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
9. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
[TBL] [Abstract][Full Text] [Related]
10. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
12. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
13. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.
Reed SD; Newton KM; Garcia RL; Allison KH; Voigt LF; Jordan CD; Epplein M; Swisher E; Upson K; Ehrlich KJ; Weiss NS
Obstet Gynecol; 2010 Aug; 116(2 Pt 1):365-373. PubMed ID: 20664397
[TBL] [Abstract][Full Text] [Related]
14. Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life.
Modesitt SC; Hallowell PT; Slack-Davis JK; Michalek RD; Atkins KA; Kelley SL; Arapovic S; Shupnik MA; Hoehn K
Gynecol Oncol; 2015 Aug; 138(2):238-45. PubMed ID: 26013696
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.
Ciccone MA; Whitman SA; Conturie CL; Brown N; Dancz CE; Özel B; Matsuo K
Arch Gynecol Obstet; 2019 Mar; 299(3):801-808. PubMed ID: 30706187
[TBL] [Abstract][Full Text] [Related]
16. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
17. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.
Uccella S; Zorzato PC; Dababou S; Bosco M; Torella M; Braga A; Frigerio M; Gardella B; Cianci S; Laganà AS; Franchi MP; Garzon S
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143933
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.
Zhou S; Xu Z; Yang B; Guan J; Shan W; Shi Y; Chen X
J Gynecol Oncol; 2021 Jul; 32(4):e57. PubMed ID: 34085795
[TBL] [Abstract][Full Text] [Related]
20. Acceptability of bariatric surgery in people with endometrial cancer and atypical hyperplasia: A qualitative study.
Kim SR; Ene GEV; Simpson A; Gesink D; Ferguson SE
Gynecol Oncol; 2023 Feb; 169():12-16. PubMed ID: 36463795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]